These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20056600)

  • 21. Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha(v)beta3.
    Ashton AW; Cheng Y; Helisch A; Ware JA
    Circ Res; 2004 Apr; 94(6):735-42. PubMed ID: 14963009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1.
    Guo NH; Krutzsch HC; Inman JK; Shannon CS; Roberts DD
    J Pept Res; 1997 Sep; 50(3):210-21. PubMed ID: 9309585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proliferation and migration activities of fibroblast growth factor-2 in endothelial cells are modulated by its direct interaction with heparin affin regulatory peptide.
    Dos Santos C; Blanc C; Elahouel R; Prescott M; Carpentier G; Ori A; Courty J; Hamma-Kourbali Y; Fernig DG; Delbé J
    Biochimie; 2014 Dec; 107 Pt B():350-7. PubMed ID: 25315978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains.
    Zhang W; Swanson R; Xiong Y; Richard B; Olson ST
    J Biol Chem; 2006 Dec; 281(49):37302-10. PubMed ID: 17040907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470).
    Chen GJ; Weylie B; Hu C; Zhu J; Forough R
    J Cell Biochem; 2007 Aug; 101(6):1492-504. PubMed ID: 17295210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
    Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
    J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity.
    Liu Z; Liu G; Zhang GL; Li J; He YQ; Zhang SS; Wang Y; He WY; Cheng GH; Yang X; Xu J; Wang J
    Oncotarget; 2016 Oct; 7(42):68473-68488. PubMed ID: 28049184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist.
    Liekens S; Bronckaers A; Belleri M; Bugatti A; Sienaert R; Ribatti D; Nico B; Gigante A; Casanova E; Opdenakker G; Pérez-Pérez MJ; Balzarini J; Presta M
    Mol Cancer Ther; 2012 Apr; 11(4):817-29. PubMed ID: 22302099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombospondins as anti-angiogenic therapeutic agents.
    Vailhé B; Feige JJ
    Curr Pharm Des; 2003; 9(7):583-8. PubMed ID: 12570805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.
    Tarkkonen K; Ruohola J; Härkönen P
    Growth Factors; 2010 Aug; 28(4):256-67. PubMed ID: 20370578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of neuroblastoma-induced angiogenesis by fenretinide.
    Ribatti D; Alessandri G; Baronio M; Raffaghello L; Cosimo E; Marimpietri D; Montaldo PG; De Falco G; Caruso A; Vacca A; Ponzoni M
    Int J Cancer; 2001 Nov; 94(3):314-21. PubMed ID: 11745408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells.
    Karagiannis ED; Popel AS
    Int J Biochem Cell Biol; 2007; 39(12):2314-23. PubMed ID: 17707681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clodronate inhibits angiogenesis in vitro and in vivo.
    Ribatti D; Maruotti N; Nico B; Longo V; Mangieri D; Vacca A; Cantatore FP
    Oncol Rep; 2008 May; 19(5):1109-12. PubMed ID: 18425365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
    Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
    Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis.
    Lundin L; Larsson H; Kreuger J; Kanda S; Lindahl U; Salmivirta M; Claesson-Welsh L
    J Biol Chem; 2000 Aug; 275(32):24653-60. PubMed ID: 10816596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
    J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of novel inhibitors of fibroblast growth factor (FGF-2) binding to heparin and endothelial cell survival from a structurally diverse carbohybrid library.
    Murphy PV; Pitt N; O'Brien A; Enright PM; Dunne A; Wilson SJ; Duane RM; O'Boyle KM
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3287-90. PubMed ID: 12392734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis.
    Sulochana KN; Fan H; Jois S; Subramanian V; Sun F; Kini RM; Ge R
    J Biol Chem; 2005 Jul; 280(30):27935-48. PubMed ID: 15923192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.